Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly reduced prices following the expiration of Boehringer Ingelheims patent. Mankind ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...

The Indian pharmaceutical market (IPM) grew by 8.4 per cent in the financial year (FY) 2025 on the back of major therapies ...

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney risks, holds significant promise for volume growth as it becomes more ...

Drugmakers have begun to roll-out their generic versions of diabetes drug Empagliflozin, on day one after the innovative blockbuster drug from Boehringer Ingelheim (BI) went off patent ...

Earlier this week, German manufacturer Boehringer Ingelheim’s patent to manufacture Empagliflozin, a medication to treat type 2 diabetes mellitus, expired in India. Empagliflozin is sold under ...

Empagliflozin is indicated to improve glycemic control in adults with type 2 diabetes mellitus. (Image Credits: Pixabay) Boehringer Ingelheim’s blockbuster diabetes drug, Empagliflozin ...

Rajeev Juneja, Vice-Chairman and Managing Director, Mankind Pharma (Image Credits: FE.com) Boehringer Ingelheim’s blockbuster diabetes Drug Empagliflozin is now off-patent in India. On Wednesday ...

Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 ...

Glenmark Pharmaceuticals announced today the launch of Empagliflozin and its fixed ... to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) while reducing cardiovascular ...